Molecular UTI Testing

About Phi Life Sciences

Phi Life Sciences is a privately held, revenue-generating laboratory services and diagnostics company founded in 2018. Its core business is divided into clinical diagnostic services for infectious diseases and genetic testing, and contract laboratory services supporting pharmaceutical and diagnostic companies with validation and clinical trial testing. The company leverages its CLIA lab to bridge innovation from the bench to commercial application, though it appears to have pivoted from its original small molecule/drug delivery focus to a service-oriented diagnostic model. Its near-term strategy relies on its COVID-19 testing franchise and expanding its menu of molecular diagnostic panels.

Therapeutic Areas

Other Urinary Tract Infection Diagnosis Drugs